RPG Life Sciences targets 25% API growth, eyes acquisition
In short
RPG Life Sciences said it wants its API business to grow 25% a year after recent acquisitions. MD Ashok Nair also said the company is looking at another acquisition within the next 12 months.
The company said the government’s cancer drug pricing changes should not have a material impact. It did not say which acquisition it may pursue or how much it could pay.
What the reporting says
RPG Life Sciences said it plans 25% compound annual growth in its API business after recent acquisitions and is evaluating another acquisition within the next 12 months. MD Ashok Nair made the remarks in CNBC TV18’s summary, and the company also said it expects no material impact from the government's cancer drug pricing changes. What remains unknown is the target size, timing, and terms of any deal.
Why it matters
RPG Life Sciences said it expects 25% CAGR growth in its API business and is reviewing another acquisition within 12 months, according to a CNBC TV18 summary. The company also said the government’s cancer drug pricing changes should not materially affect it. The reporting does not identify a target company, deal value, or whether any transaction will close.